Coverart for item
The Resource Adenocarcinoma of the Esophagogastric Junction : From Barrett's Esophagus to Cancer

Adenocarcinoma of the Esophagogastric Junction : From Barrett's Esophagus to Cancer

Label
Adenocarcinoma of the Esophagogastric Junction : From Barrett's Esophagus to Cancer
Title
Adenocarcinoma of the Esophagogastric Junction
Title remainder
From Barrett's Esophagus to Cancer
Creator
Contributor
Subject
Language
eng
Cataloging source
MiAaPQ
Literary form
non fiction
Nature of contents
dictionaries
Adenocarcinoma of the Esophagogastric Junction : From Barrett's Esophagus to Cancer
Label
Adenocarcinoma of the Esophagogastric Junction : From Barrett's Esophagus to Cancer
Link
http://libproxy.rpi.edu/login?url=https://ebookcentral.proquest.com/lib/rpi/detail.action?docID=4812457
Publication
Copyright
Related Contributor
Related Location
Related Agents
Related Authorities
Related Subjects
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • "Preface" -- "Contents" -- "Contributors" -- "1: Epidemiology and Risk Factors" -- "1.1 Methodological Issues" -- "1.2 General Overview of Cancers from the Upper Gastrointestinal Tract" -- "1.3 Incidence of EGJ Adenocarcinoma" -- "1.3.1 Geographic Variability" -- "1.3.2 Age and Sex Distribution" -- "1.3.3 Proportion of Gastric Cancer Arising from the Cardia" -- "1.3.4 Trends in Cardia Cancer" -- "1.4 Stage and Survival" -- "1.5 Risk Factors" -- "1.5.1 Genetic Factors" -- "References" -- "2: Barrettâ{u0080}{u0099}s Esophagus: Pathogenesis and Prevention" -- "2.1 Pathogenesis" -- "2.2 Prevention" -- "References" -- "3: Surveillance in Barrettâ{u0080}{u0099}s Esophagus and Dysplasia" -- "3.1 Clinical Features" -- "3.2 Endoscopic Features" -- "3.2.1 Length of the BE Segment" -- "3.2.2 Nodularity, Ulcers, or Endoscopically Visible Abnormalities" -- "3.3 Pathological Features" -- "3.4 Risk of Progression in  Non-Â{u00AD}dysplastic Barrettâ{u0080}{u0099}s Esophagus" -- "3.5 Risk of Progression and Management of BE Indefinite for Dysplasia" -- "3.6 Risk of Progression in Low-Â{u00AD}Grade Dysplasia" -- "3.7 LGD Management" -- "3.8 High-Grade Dysplasia" -- "References" -- "4: Ablation Techniques for Barrettâ{u0080}{u0099}s Esophagus and Dysplasia" -- "4.1 Introduction" -- "4.2 Ablative Techniques" -- "4.3 Radiofrequency Ablation" -- "4.3.1 Technique" -- "4.3.2 Efficacy" -- "4.3.3 Complications" -- "4.4 Cryotherapy" -- "4.4.1 Technique" -- "4.4.2 Efficacy" -- "4.4.3 Complications" -- "4.5 Photodynamic Therapy (PDT)" -- "4.5.1 Technique" -- "4.5.2 Efficacy" -- "4.5.3 Complications" -- "4.6 Argon Plasma Coagulation (APC)" -- "4.7 MPEC" -- "4.8 Endoscopic Therapy Versus Esophagectomy" -- "4.9 Postablation Surveillance" -- "4.10 Subsquamous Intestinal Metaplasia (SSIM)" -- "4.11 Recurrences and Predictors of Recurrence"
  • "4.12 Follow-Up Intervals" -- "4.13 Patient Selection and Technical Considerations" -- "References" -- "5: Endoscopic Resection for Barrettâ{u0080}{u0099}s Esophagus to Dysplasia" -- "5.1 Evidence on Barrettâ{u0080}{u0099}s" -- "5.2 Diagnosis" -- "5.3 Endoscopic Treatment" -- "References" -- "6: 7th Edition AJCC/UICC Staging: Esophagus and Esophagogastric Junction" -- "6.1 The Data" -- "6.2 The Analysis" -- "6.3 7th Edition TNM Classifications: Changes and Additions" -- "6.4 7th Edition: Nonanatomic Cancer Characteristics" -- "6.5 7th Edition Stage Groupings" -- "6.6 Esophagogastric Junction Cancers" -- "6.7 The Future: 8th Edition and Beyond" -- "6.8 Beyond Anatomic Staging" -- "References" -- "7: Siewert Classification of Adenocarcinoma of the Esophagogastric Junction: Still In or Already Out?" -- "7.1 The Esophagogastric Junction" -- "7.1.1 Definition" -- "7.1.2 Different Classification Systems" -- "7.2 The Siewert Classification of Adenocarcinoma of the EGJ" -- "7.2.1 Definition and Topographical Classification" -- "7.2.2 Diagnosis" -- "7.2.3 Epidemiological, Morphological, and Biological Differences" -- "7.2.4 Lymphatic Drainage and Metastases" -- "7.2.5 Differences in Prognosis" -- "7.2.6 Therapeutic Consequences of Siewertâ{u0080}{u0099}s Classification" -- "7.2.7 Criticism" -- "References" -- "8: Preoperative Work-Up: Conventional Radiology, CT Scan, Ultrasonography, and MRI" -- "8.1 Conventional Radiology" -- "8.2 Multi-detector Computed Tomography (MDCT)" -- "8.3 Ultrasound" -- "8.3.1 Conventional Ultrasound" -- "8.3.2 Endoscopic Ultrasound" -- "8.4 Magnetic Resonance Imaging (MRI)" -- "References" -- "9: Role of PET/CT and MRI in the Prediction of Response to Neoadjuvant Treatment" -- "9.1 Introduction" -- "9.2 PET/CT" -- "9.2.1 Evaluation During Neoadjuvant Therapy for Prognostication"
  • "9.2.2 Evaluation After Neoadjuvant Therapy for Restaging" -- "9.2.3 Evaluation After Neoadjuvant Therapy for Prognostication" -- "9.3 MRI" -- "9.3.1 Evaluation of Treatment Response for Restaging" -- "9.3.2 Evaluation of Treatment Response for Prognostication" -- "9.4 Tumor Recurrence" -- "References" -- "10: Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma" -- "10.1 Growth Factor Receptors" -- "10.1.1 Epidermal Growth Factor Receptor" -- "10.1.2 Human Epidermal Growth Factor Receptorâ{u0088}{u0092}2" -- "10.2 Chemotherapy Metabolism- Related Biomarkers" -- "10.3 Apoptosis-Related Biomarkers" -- "10.3.1 p53" -- "10.3.2 Nuclear Factor Kappa B (NF-kB)" -- "10.3.3 Baculoviral Inhibitor of Apoptosis Repeat-Â{u00AD}Containing 3 Gene" -- "10.4 Leptin" -- "10.5 Aldehyde Dehydrogenase" -- "10.6 Genomic Signatures" -- "References" -- "11: Pathological Response to Neoadjuvant Treatment: More Questions Than Answers" -- "11.1 Introduction" -- "11.2 TNM Staging System" -- "11.3 Histopathological Response in Siewert I and II" -- "11.4 Histopathological Response in Siewert III" -- "References" -- "12: Hospital Volume and Centralization in EGJ Cancer" -- "References" -- "13: Patient Selection and Tailored Treatment Principles" -- "13.1 Introduction" -- "13.2 Predictors of Morbidity and Mortality" -- "13.3 Patientsâ{u0080}{u0099} Characteristics" -- "13.3.1 Body Mass Index" -- "13.3.2 Age" -- "13.3.3 Pulmonary Condition" -- "13.3.4 Cardiovascular Status" -- "13.3.5 Hepatic Dysfunction" -- "13.4 Tailored Treatment Principles" -- "References" -- "14: How to Treat EGJ Cancer: Indications and Treatment Strategy" -- "14.1 Introduction" -- "14.2 T1m" -- "14.3 â{u0089}{u00A5}T1sm" -- "14.3.1 Resection Margins" -- "14.3.1.1 Longitudinal Margins" -- "14.3.1.2 CRM"
  • "14.3.2 Type of Lymphadenectomy" -- "14.3.2.1 General Issues on Lymphadenectomy" -- "14.3.2.2 Nodal Involvement by T" -- "14.3.2.3 Nodal Spread by Site" -- "Siewert I" -- "Siewert II" -- "Siewert III" -- "14.3.2.4 Extent of Lymphadenectomy" -- "14.3.3 Treatment Strategy" -- "14.3.3.1 Siewert I" -- "14.3.3.2 Siewert II" -- "14.3.3.3 Siewert III" -- "References" -- "15: Chemotherapy in Oesophagogastric Junctional Cancer" -- "15.1 Introduction" -- "15.2 Neoadjuvant Chemotherapy" -- "15.3 Perioperative Chemotherapy" -- "15.4 Inoperable and Metastatic EGJ Cancer" -- "15.5 Targeted Agents" -- "15.5.1 HER2-Targeting Agents" -- "15.5.2 Anti-angiogenesis Agents" -- "References" -- "16: Chemoradiation in Esophagogastric Junction Cancer" -- "16.1 Introduction" -- "16.1.1 Classification of Junctional Tumors" -- "16.1.2 Rationale for Combination of Chemotherapy and Radiotherapy" -- "16.2 Definitive Chemoradiotherapy" -- "16.2.1 Definitive Chemoradiotherapy Versus Definitive Radiotherapy Alone" -- "16.2.2 Dose of Radiotherapy in Definitive Chemoradiotherapy" -- "16.2.3 Sequential Versus Concurrent Chemoradiotherapy" -- "16.2.4 Salvage Surgery" -- "16.2.5 Definitive Chemoradiotherapy Versus Surgery Alone" -- "16.3 Neoadjuvant Chemo- and/or Radiotherapy Plus Surgery" -- "16.3.1 Neoadjuvant Radiotherapy Plus Surgery" -- "16.3.2 Neoadjuvant Chemotherapy Plus Surgery" -- "16.3.3 Neoadjuvant Chemoradiotherapy Plus Surgery" -- "16.3.4 CROSS Trial" -- "16.3.5 Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy" -- "16.4 Definitive Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Plus Surgery" -- "16.5 Future Perspectives" -- "16.5.1 Classification by Location and Histology" -- "16.5.2 Dose Escalation in Definitive Chemoradiotherapy" -- "16.5.3 Surgery as Needed Approach" -- "References"
  • "17: Signet Ring Carcinoma in EGJ: What Is It?" -- "17.1 Epidemiology" -- "17.2 Pathology" -- "17.3 Clinical Behavior and Preoperative Workup" -- "17.4 Neoadjuvant Therapy and Surgical Treatment" -- "17.5 Adjuvant Treatment" -- "References" -- "18: Morbid-Mortality and Treatment of Complications" -- "18.1 Introduction" -- "18.2 Patient Selection" -- "18.3 Medical Complications" -- "18.3.1 Cardiac Complications" -- "18.3.2 Pulmonary Complications" -- "18.4 Surgical Complications" -- "18.4.1 Anastomotic Leak" -- "18.4.2 Diagnosis and Treatment" -- "18.4.3 Conduit Necrosis" -- "18.5 Chylothorax" -- "References" -- "19: Long-Term Results with Surgery Alone and Multimodal Treatments" -- "19.1 Introduction" -- "19.2 Long Term with Surgery Alone" -- "19.3 Long Term with Multimodal Treatments" -- "19.4 Recurrence" -- "References" -- "20: Open or Minimally Invasive? Comparison of Early and Late Results" -- "20.1 Introduction" -- "20.2 MIE Techniques" -- "20.3 Early Results (Tables 20.1 and 20.2)" -- "20.4 Long-Term Results (Table 20.3)" -- "20.5 Randomized Controlled Trials" -- "References" -- "21: Enhanced Recovery After Surgery (ERAS) and Nutritional Aspects" -- "21.1 Introduction" -- "21.2 Evolution of ERAS After Esophagectomy" -- "21.3 The Core Components of ERAS After Esophagectomy" -- "21.3.1 Preoperative" -- "21.3.1.1 Focussed Counseling and Psychological Preparation" -- "21.3.1.2 Physical Preparation for Esophagectomy" -- "21.3.2 Intraoperative" -- "21.3.2.1 Surgical Management" -- "21.3.2.2 Anesthetic Management" -- "21.3.3 Postoperative" -- "21.3.4 Nutrition" -- "21.3.4.1 Preoperative Assessment and Optimization" -- "21.3.4.2 Perioperative Nutritional Care" -- "Aspects of Perioperative Feeding" -- "Immuno-nutrition" -- "Reintroduction of Oral Intake"
  • "21.3.4.3 Postoperative Nutrition Support"
http://library.link/vocab/cover_art
https://contentcafe2.btol.com/ContentCafe/Jacket.aspx?Return=1&Type=S&Value=9783319287768&userID=ebsco-test&password=ebsco-test
Dimensions
unknown
http://library.link/vocab/discovery_link
{'f': 'http://opac.lib.rpi.edu/record=b4393434'}
Extent
1 online resource (278 pages)
Form of item
online
Isbn
9783319287768
Media category
computer
Media MARC source
rdamedia
Media type code
c
Sound
unknown sound
Specific material designation
remote

Library Locations

    • Folsom LibraryBorrow it
      110 8th St, Troy, NY, 12180, US
      42.729766 -73.682577
Processing Feedback ...